uniQure Q3 net loss $44.4M; cash runway through 2027; FDA meeting for Huntington gene therapy

uniQure N.V.

2024-Q3 EPS reported -$3.42 revenue$21,898,000

Net loss $44.4M ($0.91/share) vs $89.6M ($1.88) in Q3 2023; revenue $2.3M (up from $1.4M).
Cash $435.2M as of Sep 30; retired $50M debt; expects cash runway through end of 2027.
Sold Lexington facility and restructured, cutting ~65% of roles (300) and reducing cash burn by $70M/year.
Type B FDA meeting scheduled late Nov 2024 to discuss accelerated pathway for AMT-130 in Huntington's disease.
Positive interim data at 24 months: AMT-130 high dose showed significant slowing of disease progression (p=0.007) and NfL reduction (p=0.02).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.